Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL329018 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CA1CA9GSK3AGSK3B | |
| SCHEMBL7178562 | 0.81 | GSK3A (0.50) | ALDH1A1CA1CA9GSK3AGSK3B | |
| SCHEMBL7178558 | 0.81 | GSK3A (0.50) | ALDH1A1CA1CA9GSK3AGSK3B | |
| SCHEMBL13113506 | 0.77 | — | — | |
| SCHEMBL5323960 | 0.73 | — | — | |
| SCHEMBL11206389 | 0.71 | ALDH1A1 (0.48) | ALDH1A1CA1CA9GSK3AGSK3B | |
| SCHEMBL11207122 | 0.71 | ALDH1A1 (0.48) | ALDH1A1CA1CA9GSK3AGSK3B | |
| SCHEMBL27757153 | 0.70 | ALDH1A1 (0.54) | ALDH1A1CA1CA9 | |
| SCHEMBL6625847 | 0.69 | — | — | |
| SCHEMBL24628 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2407444-A2 | Process for the preparation of dodecanedioic acid | Invista Technologies S.a r.l. (CH) | 2012-01-18 | — | — | EP | disclosed |
| EP-2257516-A2 | METHODS OF MAKING CYCLODODECATRIENE AND METHODS OF MAKING LAUROLACTONE | Invista Technologies S.à.r.l. (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009117498-A2 | METHODS OF MAKING CYCLODODECATRIENE AND METHODS OF MAKING LAUROLACTONE | INVISTA TECHNOLOGIES S.A R.L. (CH) | 2009-09-24 | — | — | WO | disclosed |
| US-20090240068-A1 | METHODS OF MAKING CYCLODODECATRIENE AND METHODS OF MAKING LAUROLACTONE | INVISTA NORTH AMERICA S.A.R.L. (US) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240068-A1 | METHODS OF MAKING CYCLODODECATRIENE AND METHODS OF MAKING LAUROLACTONE | SCD, DHCR7, LIPA | ALDH1A1 1889/4885CA1 2831/4885CA9 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.